A Ohio overview of physician-supervised GLP-1 treatment through Astra, including local access context and the cities we cover. Every statistic on this page links to its source.
36.9% of Ohio adults have obesity, according to the CDC's 2024 BRFSS prevalence estimates 1, above the national adult rate of 33.1% 1. Applied to the state's 11,883,304 residents 2, that prevalence describes roughly 3,420,253 adults — a figure modelled from those two published numbers rather than counted by either agency.
Ohio is the strictest state on this page's list, and not because of its telehealth law. The Ohio Board of Pharmacy has narrowed compounded GLP-1 dispensing further than most boards have, and any page that sells you a plan here without saying that is leaving out the part you would want to know first.
Nothing about our price is Ohioan.
Astra's pricing is the same in every state we serve: compounded semaglutide from $68 per month and compounded tirzepatide from $118 per month on 12-month plans, or $145 and $250 per month when billed monthly. There is no local price list, no regional surcharge, and no state-specific discount.
The same number appears on an invoice in Toledo, Athens, and Cleveland. What differs by state is not what we charge but what a pharmacy is permitted to dispense, which is the subject of the two sections below.
Ohio Medicaid does not cover GLP-1 medications for weight loss alone. The benefit reaches these drugs through diabetes indications, so a member whose only indication is obesity will not be approved for Wegovy or Zepbound on that basis.
Ohio is with the majority here rather than the exception: only about ten state Medicaid programs still covered GLP-1s for obesity as of mid-2026, and KFF's tracking of state Medicaid GLP-1 policy is the clearest public record of where each program landed 3.
Commercial coverage in Ohio varies, and the employer decides it more than the state does. A hospital system, a manufacturer, and a university in the same county can give three different answers, because weight-management drug coverage is a benefit each plan sponsor elects or declines. Check the formulary for your specific plan year rather than a carrier's general marketing page.
What to do next: search your plan-year drug list for Wegovy, Zepbound, and the phrase "weight management". If the drugs appear, ask the plan for its prior-authorization criteria in writing. If they are excluded, or you are an Ohio Medicaid member whose only indication is weight, the realistic routes are a documented comorbidity appeal, a manufacturer direct-pay program for the branded product, or a cash-pay physician-supervised program such as Astra's.
Yes. Ohio law authorizes licensed providers to treat Ohio patients through telehealth — including an initial visit conducted by synchronous or asynchronous technology — as long as the visit meets the same standard of care as in-person care, and no prior in-person exam is required to prescribe non-controlled medications (Ohio Revised Code 4743.09, current version effective April 9, 2025 4; State Medical Board rule OAC 4731-37-01 5). Rules for compounded medications are set separately, under federal law (Section 503A) and by the Ohio Board of Pharmacy, and they have changed through 2025 and 2026: after FDA removed tirzepatide and semaglutide from its drug-shortage list, the Board's July 17, 2025 guidance confirms that compounding versions that are essentially copies of the brand products is no longer permitted, and that a compounded GLP-1 may be prepared only under narrow 503A exceptions, such as a prescriber-documented change that makes a significant difference for the individual patient 6. The Board also prohibits the use of semaglutide or tirzepatide salt forms in compounding 6.
That is a stricter reading than several neighbouring states apply, and we would rather state it plainly than let an Ohio patient discover it after paying. If a compounded formulation is not appropriate for you under those conditions, a licensed provider will tell you so during the evaluation instead of after.
Our provider group holds Ohio licensure and our partner pharmacies are licensed to dispense into the state, so a patient in Appalachian Ohio or the northwest counties can be evaluated at home rather than driving to a metro obesity-medicine clinic — subject to the Board of Pharmacy conditions described above.
Astra treats patients in Ohio through state-licensed physicians.
City pages carry local access context — county figures, clinician supply, and what the local market charges — under the same sourcing rules as this page.
Not for weight loss alone. Ohio Medicaid reaches GLP-1 medications through diabetes indications only, so obesity by itself is not a covered reason. As of mid-2026 only about ten state Medicaid programs still covered GLP-1s for obesity.
No, and that is deliberate. Astra charges one price in every state it serves, published once in the cost section above. There is no Ohio price list, no regional surcharge, and no local discount.
No. Ohio Revised Code 4743.09 authorizes licensed providers to treat Ohio patients through telehealth, including an initial visit by synchronous or asynchronous technology, with no prior in-person exam required to prescribe non-controlled medications, provided the visit meets the same standard of care as in-person care. State Medical Board rule OAC 4731-37-01 governs how that care is delivered.
Only in limited circumstances. Because semaglutide is no longer on the FDA's drug-shortage list, Ohio Board of Pharmacy guidance (July 17, 2025) confirms that pharmacies cannot compound versions that are essentially copies of Ozempic or Wegovy; a compounded formulation is permissible only when it meets federal 503A conditions — chiefly, a change your prescriber documents as making a significant clinical difference for you specifically — and salt forms of semaglutide are prohibited. Whether a compounded option is appropriate is a determination your licensed provider makes on an individual basis.
Tell your care team your new address before your next refill. Treatment is tied to the state you are located in when you are seen, so a provider licensed in your new state has to take over and the pharmacy has to be licensed to dispense there. If Astra serves your new state we move the plan across without restarting it; if we do not, we say so and stop billing rather than shipping into a state we are not licensed in.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.